PPARGC1A and cardiomyopathy: Our findings are crucial for the development of novel therapeutic approaches such as targeting the HO-1–SIRT1–PGC-1α axis to prevent cardiomyopathy and heart failure, which is a major source of morbidity and mortality in diabetic patients.